Table 12.

Dosage of THC and CBD administered with hybrid medical cannabis to Italian fibromyalgia patients for at least 3 months

Patient	Hybrid MC (Bediol and FM2), N = 18
	Decoction		Oil extract
	THC (mg)	CBD (mg)	THC (mg)	CBD (mg)
Patient #1	6	8	0.66	0.55
Patient #2
Patient #3	24	32
Patient #4	36	48	3.9	3.3
Patient #5	23.6	38
Patient #6			3.12	2.64
Patient #7	6	8	0.78	0.66
Patient #8	33	50
Patient #9	26.4	40
Patient #10	39.6	60
Patient #11			4.68	3.96
Patient #12	23.6	38	1.56	1.32
Patient #13
Patient #14
Patient #15
Patient #16	19.8	30
Patient #17			1.8	1.65
Patient #18	19.8	30
Median	23.6	38	1.8	2
IQR	13.2	18	3.12	2.64
Mean	23.4	34.7	2.4	2
± SD	10.7	16.1	1.6	1.3

MC medical cannabis, THC Δ-9-tetrahydrocannabinol, CBD cannabidiol, N number of patients, IQR interquartile range, ± plus/minus, SD standard deviation. The table shows the quantity of THC and CBD administered with hybrid medical cannabis to 18 patients with fibromyalgia syndrome treated with medical cannabis for at least 3 months at an Italian pain clinic. Hybrid medical cannabis is the one with a similar content of Δ-9-tetrahydrocannabinol and cannabidiol